Critical Analysis: Pharmaxis (OTCMKTS:PXSLY) and Zomedica (OTCMKTS:ZOMDF)

Profitability

This table compares Pharmaxis and Zomedica’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pharmaxis	N/A	N/A	N/A
Zomedica	-255.53%	-30.63%	-28.09%

Valuation & Earnings

This table compares Pharmaxis and Zomedica”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharmaxis	$8.75 million	3.03	-$9.36 million	N/A	N/A
Zomedica	$32.03 million	3.03	-$81.86 million	($0.09)	-1.10

Pharmaxis has higher earnings, but lower revenue than Zomedica.

Insider & Institutional Ownership

9.0% of Zomedica shares are owned by institutional investors. 5.6% of Zomedica shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Pharmaxis has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Zomedica has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.

Summary

Pharmaxis beats Zomedica on 5 of the 9 factors compared between the two stocks.

About Pharmaxis

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

About Zomedica

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.